Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    Menu

    Siponimod

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 354,693Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aurobindo Pharma’s Generics Siponimod Receives Approval in US
    Aurobindo Pharma’s Generics Siponimod Receives Approval in US

    06 Mar 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218459

    FDA
    06 Mar 2026
    Share Share
    Lupin Receives Tentative U.S. FDA Approval For Siponimod Tablets
    Lupin Receives Tentative U.S. FDA Approval For Siponimod Tablets

    05 Dec 2025

    // PRESS RELEASE

    https://www.lupin.com/lupin-receives-tentative-approval-from-u-s-fda-for-siponimod-tablets/

    PRESS RELEASE
    05 Dec 2025
    Share Share
    NICE recommends siponimod for treating secondary progressive MS
    NICE recommends siponimod for treating secondary progressive MS

    15 Oct 2020

    // PHARMAFILE

    http://www.pharmafile.com/news/561675/nice-recommends-siponimod-treating-secondary-progressive-ms

    PHARMAFILE
    15 Oct 2020
    Share Share
    Novartis data show early treatment with Mayzent delays disability progression
    Novartis data show early treatment with Mayzent delays disability progression

    14 Sep 2020

    // PRESS RELEASE

    https://www.novartis.com/news/media-releases/novartis-data-show-early-treatment-mayzent-siponimod-delays-disability-progression-and-show-benefits-cognitive-performance-patients-secondary-progressive

    PRESS RELEASE
    14 Sep 2020
    Share Share
    Novartis Responds to NICE Decision on Siponimod
    Novartis Responds to NICE Decision on Siponimod

    25 Jun 2020

    // PHARMTECH

    http://www.pharmtech.com/novartis-responds-nice-decision-siponimod

    PHARMTECH
    25 Jun 2020
    Share Share
    China approves Novartis' multiple sclerosis treatment Mayzent
    China approves Novartis' multiple sclerosis treatment Mayzent

    12 May 2020

    // Roxanne Liu REUTERS

    https://www.reuters.com/article/us-novartis-china-multiple-sclerosis/china-approves-novartis-multiple-sclerosis-treatment-mayzent-idUSKBN22L0C6?feedType=RSS&feedName=healthNews

    Roxanne Liu REUTERS
    12 May 2020
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.